triazolam has been researched along with Breast Neoplasms in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No clinically significant adverse reactions were encountered and no adverse reactions occurred more frequently in the triazolam group than in the placebo group." | 2.67 | Hypnotic efficacy and safety of triazolam administered during the postoperative period. ( Holland, JC; Jacobsen, PB; Kinne, DW; Massie, MJ, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobsen, PB | 1 |
| Massie, MJ | 1 |
| Kinne, DW | 1 |
| Holland, JC | 1 |
1 trial available for triazolam and Breast Neoplasms
| Article | Year |
|---|---|
Hypnotic efficacy and safety of triazolam administered during the postoperative period.
Topics: Adult; Aged; Analysis of Variance; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind | 1994 |